Thrombophilia Screening After Severe IUGR
Sponsor
Central Hospital, Nancy, France (Other)
Overall Status
Recruiting
CT.gov ID
NCT05551078
Collaborator
(none)
100
1
3.5
28.2
Study Details
Study Description
Brief Summary
This retrospective study aims to assess the input of thrombophilia screening in pregnant women with severe intra-uterine growth restricted babies.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
100 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
Thrombophilia Screening in Women After Severe IUGR
Actual Study Start Date
:
Sep 15, 2022
Anticipated Primary Completion Date
:
Oct 1, 2022
Anticipated Study Completion Date
:
Jan 1, 2023
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
pregnant women with severe IUGR
|
Biological: thrombophilia screening
In the IUGR group systematic thrombophilia screening had already been performed.
|
Outcome Measures
Primary Outcome Measures
- Rate of positive's thrombophilia screening [5 years]
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Women over 18 years old
-
Pregnant women
-
IUGR defined by an EFW <3rd centile
-
IUGR before 25 GW
Exclusion Criteria:
- none
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Matthieu Dap | Nancy | France | 54000 |
Sponsors and Collaborators
- Central Hospital, Nancy, France
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Central Hospital, Nancy, France
ClinicalTrials.gov Identifier:
NCT05551078
Other Study ID Numbers:
- 2022PI102
First Posted:
Sep 22, 2022
Last Update Posted:
Sep 22, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: